Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2023-05-31 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Theralase Technologies Inc. dated May 30, 2023, discussing the release of their 1Q2023 unaudited condensed interim consolidated financial statements. It includes detailed financial data for the quarter ended March 31, 2023, such as revenue, expenses, and net loss, as well as operational highlights including leadership changes, clinical study updates, and warrant extensions. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement of a report or a certification letter, but includes actual financial statements and detailed interim results. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-05-31 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Theralase Technologies Inc. dated May 30, 2023, announcing the release of their 1Q2023 unaudited condensed interim consolidated financial statements. It contains detailed financial data for the three-month period ended March 31, 2023, including revenue, expenses, and net loss figures. The document also discusses operational highlights such as leadership changes, clinical study updates, and presentations at scientific conferences. The presence of comprehensive financial data for a quarter, including income statement details and operational commentary, indicates this is an Interim / Quarterly Report rather than a brief earnings release or a simple announcement. The document length (15,000 characters) and the inclusion of substantive financial statements and analysis confirm it is a full interim report, not just a notification or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2023-05-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F2 Certification of Interim Filings Full Certificate by the CFO of Theralase Technologies Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. The document is primarily an officer certification attesting to the accuracy and completeness of the interim filings, including disclosure controls and internal controls over financial reporting. It does not contain the actual interim financial statements or substantive financial data but serves as a regulatory attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3224 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-05-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO, certifying the accuracy and fairness of the interim financial report and interim MD&A for the period ended March 31, 2023. It contains no actual financial data or analysis but is an officer certification as per National Instrument 52-109. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3261 characters) and is a certification letter, not the full interim report.
2023-05-31 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management's Discussion and Analysis of Financial Condition and Operations' (MD&A) for Theralase Technologies Inc. It references the unaudited condensed interim consolidated financial statements for the three-month period ended March 31, 2023, indicating it is related to a quarterly or interim period. The content includes detailed discussion of business operations, forward-looking statements, company profile, leadership changes, and clinical study updates. The document length is 15,000 characters, which is substantial and contains substantive financial and operational analysis. The presence of MD&A and reference to interim financial statements aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or certification, nor is it a full annual report or earnings release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2023-05-31 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new President and CEO for Theralase Technologies Inc. It includes background information on the company, details about a clinical study, and forward-looking statements. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content focuses on management changes and company updates rather than financial results or governance rules. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-05-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.